Intermountain’s goal of providing better health outcomes and more affordable care corresponds perfectly with our own quest to provide rapid diagnoses, more accurate treatments, and preventive medicine through genomics.

Provo-based Tute Genomics has closed a $3.9 million Series A1 round, with participation from Intermountain Healthcare, Healthbox, and Tencent.

“Intermountain has made a strong commitment to innovation and entrepreneurship within the healthcare system,” Reid Robison, CEO of Tute Genomics, said in a statement. “Intermountain’s goal of providing better health outcomes and more affordable care corresponds perfectly with our own quest to provide rapid diagnoses, more accurate treatments, and preventive medicine through genomics. Other forward-looking healthcare organizations are certain to follow Intermountain’s lead, as tomorrow’s healthcare will be driven by technological innovations.”

The healthcare industry is notoriously slow to change — understandably so, considering actual lives hang in the balance. Tute’s continued rise is helping to change that, as more and more healthcare professionals are starting to realize that as technology continues to advance, medicine and healthcare can progress along with it.

To learn more about the world of genome sequencing, read our profile on Tute Genomics’ mission to personalize medicine.

Published 6/16/2015